Profound Medical Corp. PROF

Company Overview

Profound Medical Corp. is a Canadian medical technology company focused on the development and commercialization of image-guided, minimally invasive therapeutic systems for the treatment of prostate disease, uterine fibroids, and other conditions. The company operates within the medical device and healthcare technology industries, with a primary emphasis on magnetic resonance imaging (MRI)-guided ultrasound therapies. Its core revenue drivers include sales and leasing of therapeutic systems, recurring consumables, service agreements, and procedure-related utilization associated with its proprietary platforms.

The company’s principal products are the TULSA-PRO system and the Sonalleve platform. TULSA-PRO is designed for MRI-guided transurethral ultrasound ablation of prostate tissue, including treatment for localized prostate cancer and benign prostatic hyperplasia. Sonalleve is an MRI-guided high-intensity focused ultrasound (HIFU) platform primarily used for uterine fibroids and palliative pain treatment for bone metastases in certain international markets. Profound Medical was founded in 2008 and evolved from an early-stage therapeutic ultrasound developer into a commercial-stage medical technology company with regulatory clearances in multiple jurisdictions, including the United States, Europe, and select Asian markets.